Artiva Biotherapeutics
ARTV | NASDAQ
$3.96
-$0.05 (-1.25%)
At close: Nov 16, 2026, 4:00 PM ET
$3.94
-$0.02 (-0.51%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Artiva Biotherapeutics Company Profile
Company profile explainedCompany Profile
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Fred Aslan | CEO, Principal Financial & Accounting Officer and Director |
| Jennifer Kinsbruner Bush | Chief Operating Officer |
| Andrew Cronauer | VP, General Counsel & Corporate Secretary |
| Benjamin Dewees | Senior Vice President of Regulatory Affairs |
| Christopher Horan | Chief Technical Operations Officer |
| David Moriarty | Senior Vice President of Clinical Operations |
| Feng Xu | Senior Vice President of Biometrics |
| Gines Diego Miralles | President and Head of Research & Development |
| Heather Raymon | Senior Vice President of Research & Early Development |
| Nicholas Veomett | Vice President of Corporate Development |
| Peter Flynn | Co-Founder & Strategic Advisor |
Artiva Biotherapeutics
| Country | United States |
| IPO Date | Jul 19, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 115 |
| CEO | Fred Aslan |
Contact Details
5505 Morehouse Drive San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | ARTV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001817241 |
| CUSIP Number | 04317A107 |
| ISIN Number | US04317A1079 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove ARTV